Efficacy and safety of oxaliplatin and capecitabine in combination with sintilimab as first-line treatment for HER2-negative advanced gastric cancer
Journal Title: Chinese Journal of Clinical Research - Year 2025, Vol 38, Issue 1
Abstract
"<b>Objective</b> To analyze the clinical efficacy and the occurrence of adverse events of the oxaliplatin and capecitabine (XELOX) combined with sintilimab as a first-line treatment in patients with human epidermal growth factor receptor2 (HER2)-negative advanced gastric cancer(GC). <b>Methods</b> Eighty patients with HER2-negative GC admitted to the Affiliated Hospital of Xuzhou Medical University between February 2021 and December 2022 were prospectively selected. Patients were randomly assigned to the observation group and the control group, with 40 cases in each group. The control group was treated with XELOX regimen alone, and the observation group was treated with XELOX plus sintilimab. The clinical efficacy, progression-free survival (PFS), and incidence of adverse events were compared between the two groups. <b>Results</b> After three treatment cycles, the objective response rate (ORR) and disease control rate (DCR) in the observation group were higher than those in the control group (62.50%vs 40.00%,χ2 =4.053,P <0.05; 95.00%vs 72.50%,χ2=7.440,P <0.01）. The median PFS (mPFS) was 232.5 days in the observation group, compared to 154 days in the control group, showing a statistically significant improvement (P<0.05). Among programmed cell death ligand-1 (PD-L1) high-expression patients, the efficacy in the observation group was significantly superior to that in patients with PD-L1 low-expression (P <0.05). Additionally, the efficacy of PD-L1 low-expression patients in the observation group was higher than that of PD-L1 low-expression patients in the control group (Z =2.347,P <0.05). The incidence of treatment-related adverse events was not significantly different between the two groups (P >0.05). <b>Conclusion</b> The combination of XELOX and sintilimab demonstrates superior clinical efficacy and manageable safety in patients with HER2-negative advanced GC compared to XELOX alone. The regimen is particularly effective in improving the prognosis of patients with high PD-L1 expression."
Authors and Affiliations
ZHANG Xiaorui, SHAN Haixia, ZHU Zhengqiu
Keywords
Related Articles
- EP ID EP759889
- DOI -
- Views 20
- Downloads 0
Progress in clinical application of esketamine combined with other anesthetic drugs
Esketamine is an N-methyl-D-aspartic acid (NMDA) receptor antagonist, which has a better effect than ketamine in anesthesia. Esketamine can act on the nervous system, respiratory system, circulatory system, etc. Due to i...
Effect of reduced glutathione in combination with sodium dimercaptosulphonate in the treatment of neurological Wilson‘s disease
"<b>Objective</b> To evaluate the effectiveness and safety of reduced glutathione (rGSH) in combination with sodium dimercaptosulphonate (DMPS) for neurological Wilson’s disease (NWD), and to explore the effect of the c...
Prognostic value of peripheral blood neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with gastric cancer
"<b>Objective</b> To determine the predictive value of peripheral blood neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) in the prognosis of patients with gastric cancer. <b>Methods</b> A...
Correlation study between insulin resistance index and non-alcoholic fatty liver disease
Objective To explore the relationship between homeostasis model assessment of insulin resistance index (HOMA-IR) and non-alcoholic fatty liver disease (NAFLD). Methods The registered participants aged 18 years or older i...
Effects of laparoscopic sleeve gastrectomy on sex hormones in male patients with obesity
"<b>Objective</b> To evaluate the changes in sex hormone levels in male patients with obesity after receiving laparoscopic sleeve gastrectomy (LSG). <b>Methods</b> Forty-three male obese patients who received LSG at th...